Posted by Michael Wonder on 11 Sep 2017
Research and development spending to bring a single cancer drug to market and revenues after approval
11 September 2017 - Prasad & Mailankody have estimated research and development spending for developing a new cancer drug.
In this analysis of US Securities and Exchange Commission filings for 10 cancer drugs, the median cost of developing a single cancer drug was $648.0 million. The median revenue after approval for such a drug was $1658.4 million.
These results provide a transparent estimate of research and development spending on cancer drugs and show that the revenue since approval is substantially higher than the pre-approval research and development spending.
